217313-83-2

Basic information

• Product Name: 4-(N',N'-DIBOC-AMINOMETHYL)-N-HYDROXYBENZAMIDINE
• Synonyms: 4-(N',N'-DIBOC-AMINOMETHYL)-N-HYDROXYBENZAMIDINE
• CAS NO: 217313-83-2
• Molecular Formula: C₁₈H₂₇N₃O₅
• Molecular Weight: 365.42
• Product Categories: pharmacetical
• Mol File: 217313-83-2.mol

Chemical Properties

• Boiling Point: 496.9°Cat760mmHg
• Flash Point: 254.3°C
• Appearance: /
• Density: 1.15g/cm³
• Vapor Pressure: 1.09E-10mmHg at 25°C
• Refractive Index: 1.526
• CAS DataBase Reference: 4-(N',N'-DIBOC-AMINOMETHYL)-N-HYDROXYBENZAMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(N',N'-DIBOC-AMINOMETHYL)-N-HYDROXYBENZAMIDINE(217313-83-2)
• EPA Substance Registry System: 4-(N',N'-DIBOC-AMINOMETHYL)-N-HYDROXYBENZAMIDINE(217313-83-2)

Safety Data

• Hazardous Substances Data: 217313-83-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C18H27N3O5/c1-17(2,3)25-15(22)21(16(23)26-18(4,5)6)11-12-7-9-13(10-8-12)14(19)20-24/h7-10,24H,11H2,1-6H3,(H2,19,20)

Upstream product

• 172348-74-2 tert-butyl ((tert-butoxycarbonyl)(4-cyanobenzyl)amino)-methanoate 
• 51779-32-9 iminodicarboxylic acid di-tert-butyl ester 
• 17201-43-3 4-cyanobenzyl bromide 
• 870-50-8 di-tert-butyl-diazodicarboxylate 

Downstream Products

• 162694-63-5 melagatran 
• 217313-86-5 tert-butyl((4-((((benzyloxy)carbonyl)amino)(imino)methyl) benzyl)(tert-butoxycarbonyl)amino)methanoate 
• 172348-75-3 [(4-aminomethyl-phenyl)-imino-methyl]-carbamic acid benzyl ester dihydrochloride 

Relevant articles and documents

NOVEL HETEROCYCLIC COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI

The present invention relates to a compound of formula (I), wherein, Het, A, L1, R6 and R7 are as defined in the detailed description and a process for preparing the compound of formula (I). The present invention also relates to a method for combating phytopathogenic fungi.

Enhancement of hydrophobic interactions and hydrogen bond strength by cooperativity: Synthesis, modeling, and molecular dynamics simulations of a congeneric series of thrombin inhibitors

Accurately predicting the binding affinity of ligands to their receptors by computational methods is one of the major challenges in structure-based drug design. One of the potentially significant errors in these predictions is the common assumption that the ligand binding affinity contributions of noncovalent interactions are additive. Herein we present data obtained from two separate series of thrombin inhibitors containing hydrophobic side chains of increasing size that bind in the S3 pocket and with, or without, an adjacent amine that engages in a hydrogen bond with Gly 216. The first series of inhibitors has a m-chlorobenzyl moiety binding in the S1 pocket, and the second has a benzamidine moiety. When the adjacent hydrogen bond is present, the enhanced binding affinity per ?2 of hydrophobic contact surface in the S3 pocket improves by 75% and 59%, respectively, over the inhibitors lacking this hydrogen bond. This improvement of the binding affinity per ?2 demonstrates cooperativity between the hydrophobic interaction and the hydrogen bond.

Large scale preparation of protected 4-aminomethylbenzamidine. Application to the synthesis of the thrombin inhibitor, melagatran

To allow the preparation of melagatran on a multigram scale, we have investigated several approaches for the synthesis of the key intermediate 4- aminomethylbenzamidine. The only industrially suitable pathway relies on the preparation of an N-hydroxyimino